Novo Nordisk’s GLP-1 heavyweight Wegovy could soon reach many more patients in Britain after the United Kingdom’s ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

Iterum took its time launching Orlynvah, debuting the drug in August 2025, almost a full year after securing approval. That ...

The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to ...

Evotec has appointed Ashiq Khan, Ph.D., as chief commercial officer, putting an | Evotec has appointed Ashiq Khan, Ph.D., as ...

Amid a major corporate overhaul, Novo Nordisk is pruning the ranks at its production facility in Bloomington, Indiana, which ...

With conflict in the Middle East bringing on a global energy market squeeze, one major pharma supplier is raising prices ...

Despite a healthy roster of late-stage assets and a revenue turnaround in 2025, it’s no secret that Biogen has been seeking ...

With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...

Insulet has reinstated the chief commercial officer position nearly three years after eliminating the role to pursue more ...

Promotional materials for a handful of biologics have found their way into the FDA’s hot seat. | Promotional materials for a ...

After high-profile moves by Eli Lilly and other Big Pharmas to pause their U.K. | The company is looking to work out an ...